Qiagen is expanding its digital drug-discovery tooling by integrating Nvidia accelerated computing and the Nvidia BioNeMo platform into Qiagen Digital Insights’ curated biomedical knowledgebases. The goal is to increase how often biopharma researchers can use AI for evidence-linked target selection, biomarker discovery, and multi-step workflows. The system will use graph-based AI to connect biomedical knowledge graphs with natural-language queries, while also leveraging accelerated computing to help explore evidence across genes, diseases, pathways, compounds, and clinical insights. Qiagen plans an initial set of pilot programs with select partners, with broader availability expected after validation. The announcement reflects ongoing pressure on R&D teams to shorten experimental iteration cycles without losing traceability to structured evidence. By coupling retrieval and reasoning over curated graphs, Qiagen is positioning its platform as a bridge between data analysis and agentic workflow execution. For biotech users, the practical takeaway is that knowledgebase-driven AI is moving from experimentation to partner-led pilots for drug discovery operations.